H Lundbeck A/S

HLUN-A · Nasdaq Copenhagen · Healthcare

41.70DKK +1.2%last day

Price as of 2 October 2026

The price over the past year, with dividends: +22.2%

Performance

1 month

−5.1%

1 year

+22.2%

3 years, per year

+11.4%

5 years, per year

–

Largest fall, 3 years

−42.0%

Below the peak now

−5.1%

Volatility, 1 year

30.1%

Return with dividends reinvested.

Key figures

P/E

10.5

P/B

1.5

Dividend yield

2.8%

Return on equity

+14.4%

Net margin

+15.1%

Market value

6.2 bn USD

Quality, value and trend

Where H Lundbeck stands against every Nordic stock today. 100 is best.

Quality91

Profitability and a sound balance sheet over time. Better than 91% of Nordic stocks.

Value78

The price measured against earnings, assets and cash flow. Better than 78% of Nordic stocks.

Trend88

The price development over the past year. Better than 88% of Nordic stocks.

Combined99

Quality, value and trend together. Better than 99% of Nordic stocks.

About H Lundbeck

H Lundbeck A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 5,000 employees.

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis